Cytokines are important components of the immune system that can predict or influence the development of liver diseases. IL-37, a new member of the IL-1 cytokine family, exerts potent anti-inflammatory and immunosuppressive effects inside and outside cells. IL-37 expression differs before and after liver lesions, suggesting that it is associated with liver disease; however, its mechanism of action remains unclear. This article mainly reviews the biological characteristics of IL-37, which inhibits hepatitis, liver injury, and liver fibrosis by inhibiting inflammation, and inhibits the development of hepatocellular carcinoma (HCC) by regulating the immune microenvironment. Based on additional evidence, combining IL-37 with liver disease markers for diagnosis and treatment can achieve more significant effects, suggesting that IL-37 can be developed into a powerful tool for the clinical adjuvant treatment of liver diseases, especially HCC.

中文翻译：

---

IL-37在肝病中的作用及机制研究进展

细胞因子是免疫系统的重要组成部分，可以预测或影响肝脏疾病的发展。IL-37 是 IL-1 细胞因子家族的新成员，在细胞内外发挥有效的抗炎和免疫抑制作用。IL-37的表达在肝脏病变前后存在差异，提示其与肝脏疾病相关；然而，其作用机制仍不清楚。本文主要综述IL-37的生物学特性，其通过抑制炎症来抑制肝炎、肝损伤、肝纤维化，通过调节免疫微环境抑制肝细胞癌（HCC）的发展。基于更多证据，IL-37与肝病标志物结合进行诊断和治疗可以取得更显着的效果，表明IL-37可以发展成为肝病特别是HCC临床辅助治疗的有力工具。